News Image

Why NYSE:PFE qualifies as a good dividend investing stock.

By Mill Chart

Last update: Oct 6, 2023

PFIZER INC (NYSE:PFE) is a hidden gem unveiled by our stock screening tool, featuring a promising dividend outlook alongside solid fundamentals. NYSE:PFE demonstrates decent financial health and profitability while ensuring a sustainable dividend. Let's break it down further.

Looking at the Dividend

ChartMill provides a Dividend Rating for every stock, ranging from 0 to 10. This rating assesses various dividend aspects, including yield, growth, and sustainability. NYSE:PFE earns a 8 out of 10:

  • With a Yearly Dividend Yield of 5.11%, PFE is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 3.89, PFE pays a better dividend. On top of this PFE pays more dividend than 97.62% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 2.68, PFE pays a better dividend.
  • PFE has been paying a dividend for at least 10 years, so it has a reliable track record.
  • PFE has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.

What does the Health looks like for NYSE:PFE

ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NYSE:PFE, the assigned 5 reflects its health status:

  • PFE has a Altman-Z score of 2.68. This is in the better half of the industry: PFE outperforms 72.86% of its industry peers.
  • The Debt to FCF ratio of PFE (6.13) is better than 84.76% of its industry peers.
  • PFE has a Current Ratio of 2.12. This indicates that PFE is financially healthy and has no problem in meeting its short term obligations.

A Closer Look at Profitability for NYSE:PFE

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NYSE:PFE has achieved a 8:

  • With an excellent Return On Assets value of 9.75%, PFE belongs to the best of the industry, outperforming 90.95% of the companies in the same industry.
  • PFE's Return On Equity of 21.68% is amongst the best of the industry. PFE outperforms 91.90% of its industry peers.
  • PFE's Return On Invested Capital of 11.96% is amongst the best of the industry. PFE outperforms 90.00% of its industry peers.
  • The 3 year average ROIC (16.16%) for PFE is well above the current ROIC(11.96%). The reason for the recent decline needs to be investigated.
  • With an excellent Profit Margin value of 27.55%, PFE belongs to the best of the industry, outperforming 94.76% of the companies in the same industry.
  • PFE's Operating Margin of 31.21% is amongst the best of the industry. PFE outperforms 95.71% of its industry peers.
  • In the last couple of years the Operating Margin of PFE has grown nicely.
  • With a decent Gross Margin value of 68.78%, PFE is doing good in the industry, outperforming 74.29% of the companies in the same industry.

More Best Dividend stocks can be found in our Best Dividend screener.

Check the latest full fundamental report of PFE for a complete fundamental analysis.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

PFIZER INC

NYSE:PFE (4/26/2024, 7:09:35 PM)

After market: 25.45 +0.05 (+0.2%)

25.4

+0.14 (+0.55%)

PFE News

News Image7 hours ago - The Business JournalsPfizer gene therapy made in NC gets FDA approval. It costs $3.5M per dose

Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.

News Image15 hours ago - The Motley FoolIs Viking Therapeutics Incredibly Undervalued?

The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.

News Image20 hours ago - The Motley Fool3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street

Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.

News Image2 days ago - The Motley Fool3 Dividend Stocks to Buy and Hold for the Next Decade

You'll get dividends and more with these great stocks.

News Image2 days ago - InvestorPlace7 Dividend Stocks to Buy Now for Steady Returns in Any Market

Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.

News Image2 days ago - CNBCCramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly

CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.

News Image3 days ago - Market News VideoJune 7th Options Now Available For Pfizer (PFE)
News Image3 days ago - The Motley FoolWant $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks

Put your money to work by investing in these three high-quality dividend stocks.

News Image3 days ago - BloombergPfizer’s First Gene Therapy Gets Approval for Clotting Disorder

Pfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business.

News Image3 days ago - CNBCFDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder

The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B. 

News Image3 days ago - Investor's Business DailyPfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy

Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.

News Image3 days ago - Pfizer Inc.U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
PFE Links
Follow us for more